Major Objectives Behind This Study:
# To define, describe, and forecast the global Human Organoids Market on the basis of product, usability, application, end user, and region.
# To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges).
# To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market.
# To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders.
# To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa.
# To profile the key market players and comprehensively analyze their market shares and core competencies.
# To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global human organoids market.
Expected Revenue Gains During Forecast Period:
The global human organoids market size is projected to reach USD 1,901 million by 2025 from USD 850 million in 2020, at a CAGR of 17.5% during the forecast period.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468
Growth Influencing Factors:
The global human organoids market offers significant growth potential for prominent as well as emerging product manufacturers. Technological advancements, rising incidence of transplants, and increased funding and public-private investments are key factors driving the growth of the human organoids market.
Opportunity: Increasing focus on drug discovery activities
The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. This is the major factor responsible for the rising number of clinical trials conducted for studying and commercializing new drugs. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated at 356,282.
A recent study conducted by the Hubrecht Institute states that organoids have the potential to make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. The significant growth in the number of clinical trials across the globe is expected to drive the demand for advanced medical technologies, including organoid models.
Recent Developments in the Global Human Organoids Market:
# In 2020, BIOIVT (US) partnered with upcyte technologies GmbH (Germany) as the exclusive commercial worldwide distributor for its cell products and media, including cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs).
# In 2019, Hurel and Cyprotex came into partnership which enabled Cyprotex to independently validate the HµREL multi-donor coculture model for clearance studies.
# In 2019, Organovo collaborated with MCRI and Leiden University Medical Center to develop stem cell-based bioprinted tissue treatment for kidney diseases.
# In 2018, Absolute Antibody merged with Kerafast to increase access to unique reagents.
Challenge: Dearth of skilled professionals
Skilled professionals, such as researchers and technicians, are required to set up and run experiments involving organoids, and further make observations, obtain results, and analyze the obtained data. The lack of knowledge regarding the underlying scientific principles and the right choice of technique may result in several direct and indirect expenses and increase the workload and time pressure on researchers and service providers. Thus, there is a need for highly skilled personnel for interpretation, method development, validation, operation, and troubleshooting activities.
Delelopmental biology is the largest application segment of the human orgnaoids market
Developmental biology includes the production of gametes, fertilization, development of the embryo, emergence of the adult organism, and senescence. Organoids developed from stem cells or tissues in culture can be converted into structures that resemble the in vivo anatomy and physiology of intact organs. Human organoid cultures provide the potential to study the human development and model disease processes with the same depth of analysis customary for research with nonhuman model organisms. Technological advancements in the field of 3D bioprinting have shown huge potential for organ development as the culture time is very less compared to traditional methods of tissue culture. Patient-derived human organoid studies may accelerate medical research, creating new opportunities for tissue engineering and regenerative medicine and generating knowledge and tools for preclinical studies, including drug development and testing.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468
No comments:
Post a Comment